One of the defining characteristics of the malignant phenotype is the ability to evade the host immune system. Immunotherapy as a treatment modality represents a new dawn in the way we think about the treatment of a variety of malignancies. The story of immunotherapy traces its roots to its relationship with malignant melanoma. In this article, we review the intertwined history of immunotherapy and melanoma, including the early significant history, a discussion on immune mechanisms, resistance, local and systemic immunotherapeutic modalities, and speculate on possible novel future treatment options.

Original languageEnglish (US)
Pages (from-to)25-54
Number of pages30
JournalCritical Reviews in Oncology/Hematology
StatePublished - Oct 1 2016

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology


Dive into the research topics of 'Malignant melanoma—The cradle of anti-neoplastic immunotherapy'. Together they form a unique fingerprint.

Cite this